# Prime Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prime-genomics

- Industry: Biotechnology
- Headquarters: Mountain View, US
- Website: www.primegenomics.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Jun 1, 2019)
- Investors on record: 1

## About

Prime Genomics Inc. develops advanced genomic solutions to enhance healthcare outcomes. Focused on innovation, the company aims to revolutionize the genomics landscape through its specialized offerings.Founded in 2010 and headquartered in Mountain View, US, Prime Genomics Inc. specializes in genomics and biotechnology. The company has undergone significant transformations since its inception, evolving its product offerings. Robert Weigle serves as the CEO. In 2020, the company raised USD 3.50 mn in a Series A funding round led by DigitalDx Ventures, bringing its total funding to USD 3.50 mn. The company has completed 4 deals since its founding, with the most recent deal occurring on June 1, 2020.Prime Genomics Inc. specializes in providing innovative genomic solutions tailored to the healthcare sector. Its flagship products include genomic testing and analysis services, designed to address the complex challenges faced by healthcare providers. The company serves a diverse client base, including hospitals and research institutions across North America, Europe, and Asia, continually evolving its offerings to meet the dynamic demands of its clientele.The company generates revenue through a structured transaction model involving direct sales and subscription services for its genomic solutions. Clients pay a recurring fee for ongoing access to their services, alongside direct sales of flagship offerings. This dual approach supports consistent cash flow and market expansion, with pricing reflecting industry standards and the value provided to clients.Prime Genomics Inc. plans to introduce new genomic products and services in the coming years, leveraging recent funding to enhance its research and development efforts. The company is targeting expansion into European and Asian markets by 2023, aiming to broaden its geographical footprint. The funding raised in June 2020 will support these initiatives, facilitating the development of innovative solutions in genomics.

## Funding rounds

- Series A, Jun 1, 2019 — DigitalDx Ventures
- Series A, Nov 1, 2018, $3.5M — DigitalDx Ventures

## Investors

- DigitalDx Ventures (https://capitalatlas.ai/funds/digitaldx-ventures) — Series A